TITLE

Tacrolimus Rescue Therapy for Corticosteroid-Resistant and Polyclonal Antibody-Resistant Kidney Allograft Rejections

AUTHOR(S)
Naderi, Gholam Hossein; Mehraban, Darab; Ganji, Mohammad Reza; Yahyazadeh, Seyed Reza; Latif, Amir Hossein
PUB. DATE
January 2009
SOURCE
Urology Journal;Jan2009, Vol. 6 Issue 1, p31
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction: The conventional treatment of acute kidney allograft rejection consists of high-dose corticosteroids and polyclonal antibodies. We report our experience of tacrolimus rescue therapy in patients with acute rejections refractory to corticosteroids and polyclonal antibodies. Materials and Methods: A total of 34 patients with a mean age of 42.3 years and clinical diagnosis of acute kidney allograft rejection underwent tacrolimus rescue therapy when treatment with corticosteroids and polyclonal antibodies failed. Kidney allograft biopsy results were available in 21 patients. All of the patients received tacrolimus, 0.1 mg twice daily, and in those who responded to the therapy after 4 to 6 months, tacrolimus was replaced with cyclosporine. Results: Pathologic examination of 21 biopsy specimens of the kidney allografts showed acute vascular rejection in 7 patients (33.3%), acute humoral rejection in 6 (28.6%), acute cellular rejection in 3 (14.3%), and accelerated acute rejection in 3 (14.3%). Twenty-six patients (76.5%) responded to rescue therapy with tacrolimus and discharged with a mean serum creatinine level of 1.4 mg/dL (range, 1.1 mg/dL to 1.7 mg/dL). Allograft nephrectomy was done in 8 patients (23.5%) because of no response to treatment of rejection, the pathology reports of which consisted of acute vascular rejection in 5 patients and extensive necrosis in 3. Conclusion: Tacrolimus therapy is able to salvage kidney allografts with acute refractory rejection. We recommend that tacrolimus be used as an alternative to the conventional drugs used for antirejection therapy. However, severe infectious complications as a result of overt immunosuppression must be considered.
ACCESSION #
40085334

 

Related Articles

  • TACROLIMUS DOSE IN RENAL TRANSPLANTATION- DO WE HAVE AN ANSWER? Hooda, A. K.; Kumar, Arun; Varma, P. P. // Indian Journal of Nephrology;Jul-Sep2007, Vol. 17 Issue 3, p141 

    Introduction: Tacrolimus is today the pivotal immunosuppressive agent in organ transplantation. Conventional dose of tacrolimus (0.15-0.20 mg/KG BW) which was used in initial trials is associated with high incidence of new onset diabetes mellitus (NODM). Aim: To study two dosage schedules of...

  • Immunosuppressants.  // Reactions Weekly;5/3/2008, Issue 1200, p19 

    The article describes the case of three patients who developed adenoviral enteropathy. The patients, all with bowel transplants, acquired the condition while undergoing maintenance immunosuppressive therapy with tacrolimus. Two of the three patients were given additional drugs including...

  • Fatal cytomegalovirus disease in a high-risk renal transplant recipient. Tenney, Frank; Sakarcan, Abdullah // Pediatric Nephrology;2001, Vol. 16 Issue 1, p8 

    The incidence of CMV infection in pediatric renal transplant recipients has increased as immunosuppression levels deepen following the use of newer immunosuppressive agents. It has been thought that 3-5 months of anti-CMV prophylaxis offers sufficient protection for these patients. We present a...

  • E. Transplantation.  // Kidney;Jul/Aug2003, Vol. 12 Issue 4, p184 

    Presents abstracts of studies on transplantation. "Cyclosporine Withdrawal From a Mycophenolate Mofetil-Containing Immunosuppressive Regimen in Stable Kidney Transplant Recipients: A Randomized, controlled Study," by D. Abramowicz, D. Manas, M. Lao et al; "A Decade of Experience With Renal...

  • Validación del cuestionario simplificado de adherencia a la medicación (SMAQ) en pacientes con trasplante renal en terapia con tacrolimus. Ortega Suárez, F. J.; Sánchez Plumed, J.; Pérez Valentín, M. A.; Palomo, P. Pereira; Muñoz Cepeda, M. A.; Lorenzo Aguiar, D. // Nefrologia;2011, Vol. 31 Issue 6, p690 

    Background: Non-adherence to immunosuppressant medication associates to graft loss and death. The simplified medication adherence questionnaire (SMAQ) is a short and reliable instrument to assess adherence to medication. Objective: Validation of a version of the SMAQ instrument adapted for its...

  • ROLE OF PSI IN RENAL TRANSPLANTATION. Verma, P. P.; Sharma, R. K.; Kher, Vijay // Indian Journal of Nephrology;Jul-Sep2007, Vol. 17 Issue 3, p143 

    Introduction: Chronic allograft dysfunction continues to be a significant problem in renal allograft recipients despite the introduction of newer immunosuppression agents Methods: A consensus meeting of nephrologists and transplant surgeons from North Zone was organized to review the role of...

  • Steroid withdrawal, rejection and the mixed lymphocyte reaction in children after renal transplantation. Ingulli, Elizabeth; Sharma, Vijay; Singh, Anup; Suthanthiran, Manikkam; Tejani, Amir // Kidney International Supplement;Oct1993, Issue 43, pS36 

    With improved long-term graft survival after renal transplantation, cardiovascular mortality is emerging as the leading cause of death n adults and is also being reported in children. Chronic corticosteroid therapy is thought to be an important cause of post-transplant hyperlipidemia and...

  • Tuberculosis in Solid-Organ Transplant Recipients: Consensus Statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Aguado, José María; Torre-Cisneros, Julián; Fortún, Jesús; Benito, Natividad; Meije, Yolanda; Doblas, Antonio; Muñoz, Patricia // Clinical Infectious Diseases;5/1/2009, Vol. 48 Issue 9, p1276 

    Tuberculosis is a particularly important condition in solid-organ transplant recipients because of the delay in treatment caused by the difficulties involved in its diagnosis and because of the pharmacological toxicity associated with this treatment. Both treatment delay and toxicity are...

  • Complications of pediatric live-donor kidney transplantation: a single center’s experience in Egypt. El-Husseini, Amr A.; Sobh, Mohamed A.; Ghoneim, Mohamed A. // Pediatric Nephrology;Nov2008, Vol. 23 Issue 11, p2067 

    Our objective was to study the complications of chronic renal failure (CRF) among pediatric live-donor kidney transplant recipients. Between March 1976 and December 2005, 1,785 live-donor kidney transplantations were carried out at our center. Of the recipients, 292 were 20 years old or younger...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics